NCT03233438View on ClinicalTrials.gov

Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

PHASE4CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

July 24, 2017

Primary Completion Date

October 30, 2018

Study Completion Date

October 30, 2018

Conditions
Bacterial InfectionsAcute Bacterial Skin and Skin Structure Infection
Interventions
DRUG

Dalbavancin

Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.

DRUG

Usual Care

Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.

Trial Locations (1)

10065

Weill Cornell Medicine, New York

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT03233438 - Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) | Biotech Hunter | Biotech Hunter